Island Pharmaceuticals Limited 

Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; cooperative research and development agreement with the United States Army for the preparation of Phase II clinical study for ISLA-101; and supply agreement with Catalent for the manufacture of Fenretinide softgels. Island Pharmaceuticals Limited was founded in 2017 and is based in Camberwell, Australia.